Regeneron Pharmaceuticals Inc (REGN) Buy,…

Home

Daily Stock Opinions and Ratings

Regeneron Pharmaceuticals Inc (REGN)

601.65

-14.53 (2.36%)

as of Jun 10, 2026, 8:00:00 pm Market Open.

67 watching

Investor Insights

Jun 11, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Regeneron Pharmaceuticals Inc (REGN-Q) has recently faced significant challenges, particularly following disappointing results from a cancer drug trial that led to a drastic 10% drop in stock price. Analysts had anticipated a positive outcome from this trial, which makes the current downturn even more striking. Given the negative sentiment surrounding the trial results, there could be additional downgrades on the horizon, amplifying the concerns for investors. Conversely, it's worth noting that the stock has shown a remarkable 53% increase in the past six months, which suggests that despite recent setbacks, the overall trend had been positive. This mixed picture leaves investors in a precarious position, weighing potential losses against prior gains and the stock's future outlook.

Consensus

Bearish

Valuation

Overvalued

Similar

GILD

TOP PICK

A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)

BUY

Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.

PAST TOP PICK

(Past Top Pick on August 8, 2017, Down 40%) Sold his at a stop loss before things got worse. You must be ruthless in selling your losers or you'll suffer even more downside.

TOP PICK

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

HOLD

Loves the biotech sector right now. If he had to invest money in one sector right now, it would be Biotechs. He likes this company. They are positioned very well.

Showing 31 to 35 of 35 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

CNBC

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Regeneron Pharmaceuticals Inc (REGN)